Abstract 1557P
Background
Liver metastasis (LM) frequently occurs in patients with advanced gastric cancer; yet our understanding of the underlying salient biology is preliminary. Here, we performed single-cell RNA-seq in two patients with LM of gastric cancer to explore the initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer.
Methods
Single cell RNA sequencing was performed on tissues from LM of gastric cancer. Also, we downloaded the single-cell RNA-seq of hepatocellular carcinoma (HCC) and primary gastric cancer from GEO database. Seurat were applied to sort single-cell RNA-seq of LM in gastric cancer and primary gastric cancer into different clusters via feature dimension reduction and then we investigated their expression profiling, stemness initiating and enrichment pathways. Furthermore, CellChat and monocle2 were used to explore the cellular communication and regulatory network of liver metastatic microenvironment.
Results
The transcriptomes of 13305, 26373, 20207 single cells among LM of gastric cancer, HCC, and primary gastric cancer were extracted respectively. There were 14 clusters divided into epithelial cells of liver metastasis single cells. Differential gene analyses and ratio analyses in LM and corresponding primary cancers groups showed that C10 and C12 might be the LM initiating cells clusters. And they were both enriched in the positive regulation of cell migration. SOX6+ MMP7+ epithelial cells might be the LM initiating cells in gastric cancer. Cell communication and inverse temporal analysis showed that SEPP1+ macrophage and CXCL2+ cancer associated fibroblasts (CAFs) might regulate metastatic microenvironment, of which promoted cancer stem cells migration.
Conclusions
The initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer have been investigated in this study, which provided a further understanding of the potential biological mechanisms of LM in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21